| Literature DB >> 35463486 |
Yuanfeng Zhang1,2, Bing Zhang1, Weilong Zhou1, Tao Lu3.
Abstract
Background: The treatment of long-term sores and ulcers of breast cancer metastatic recurrence is a serious challenge with successful cases rarely being documented. Herein we reported a successful case using the internal vitality supporting method of Chinese herbal medicine (CHM). Case Summary: A 59-year-old female Chinese patient, 10 years after breast cancer surgery, developed metastatic lesions in the lung. Thereafter she received radiofrequency ablation and adjuvant treatments for 1 year with severe sequelae, a right unhealed sore and ulcer. She became frustrated and depressive. And subsequently sought exclusive treatment under the guidance of a Traditional Chinese Medicine (TCM) physician. The patient's condition was categorized as a Qi (or vitality) deficiency-related sore and ulcer. In the next six months, the patient still follows a traditional Chinese medicine therapeutic regimen based on the internal vitality supporting method of Chinese herbs.Entities:
Keywords: Chinese herbal medicine; breast cancer survivors; cancer metastatic recurrence; post-radiofrequency ablation wound; psychosocial support; sore and ulcer
Year: 2022 PMID: 35463486 PMCID: PMC9027808 DOI: 10.3389/fpsyt.2022.874691
Source DB: PubMed Journal: Front Psychiatry ISSN: 1664-0640 Impact factor: 4.157
Figure 1The timeline for medical history and treatment.
Figure 2Sore and ulcers. (A) Severe sore at the first visit (with eight ulcers on right chest). (B–E) By the second and fifth visits, the sore and ulcers were significantly improved. (F) At the sixth visit, the ulcers had already healed.
Tumor marker test.
|
|
|
|
|
|
|---|---|---|---|---|
|
|
| |||
| CA15-3 | 14.17 | 13.11 | 0.00~25.00 | U/ml |
| CA125 | 7.12 | 6.97 | 0.00~35.00 | U/ml |
| CEA | 1.42 | 2.02 | 0.00~5.00 | ng/ml |
| CA19-9 | – | 21.43 | 0.00~35.00 | U/ml |
CA15-3, carbohydrate antigen 153; CA125, carbohydrate antigen 153; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 199.